Abstract: Distinguishing desmoplastic melanomas (DMs) from neurofibromas (NFs) can be histologically challenging in some cases. To date, a reliable marker to differentiate the 2 entities has remained elusive. S100 subtyping and CD34 fingerprinting have been proposed, but controversy remains as to their reliability. Missense mutations in TP53 are often found in DMs, resulting in a dominant negative effect and paradoxical accumulation of the tumor suppressor protein p53. We hypothesized that p53 may be expressed differentially in DMs, making it a valuable tool in differentiating DMs from NFs. (mean, 203; median, 260). Nuclear accumulation of p53 was seen in all 19 positive DMs. None of the 20 NFs were positive for p53 (2-tailed t test P-value <0.0001). Detection of p53 by immunohistochemistry can help to distinguish DMs from NFs.
F irst described in 1971 by Conway et al, desmoplastic melanoma (DM) is a rare variant of melanoma that is characterized by an infiltrative malignant spindle cell tumor with marked interstitial fibrosis and collagenization. 1, 2 Clinically, DM can simulate amelanotic lesions resembling scars, making the diagnosis difficult. Histologically, DM also presents a diagnostic challenge as it is often confused with neurofibroma (NF). [3] [4] [5] These 2 entities share similar immune-phenotyping profiles: S100 and SOX-10 positive but Melan-A and HMB-45 negative, making the differentiation between DM and NF difficult in some cases, even with immunohistochemistry. 6 Previous studies have suggested that various S100 family protein members may be differentially expressed in DMs compared with NFs, and that the subtype S100A1 is often found in DM and not NF. 4 However, the commonly used polyclonal S100 antibody does not differentiate the subtypes and also stains immature fibroblasts, epithelioid granulomas, and histiocytic proliferations in scars and may be inferior to SOX-10. 7 CD34 fingerprint immune-reactivity has been shown to be more prominent in NFs compared with DM 5 but this has been controversial as a similar pattern was observed in an early DM by a different group. 3 Thus, a reliable marker to differentiate between DM and NF remains elusive.
From a genetic standpoint, DM is unique from conventional melanomas. It lacks classic mutations such as BRAF, NRAS, and KIT, instead harboring a higher frequency of loss of function NF1 mutations. [8] [9] [10] [11] Exome sequencing showed that DM carries a significantly higher mutation burden compared with other melanomas with ultraviolet radiation as the dominant mutagen. 12 It was also shown that missense mutations in TP53 are often found in DMs, resulting in a dominant negative effect and paradoxical accumulation of the tumor suppressor protein p53. Given these findings, we hypothesized that p53 staining may be expressed differentially in DMs, making it a valuable tool in differentiating DMs from NFs. To test our hypothesis, we compared p53 protein expression in 20 DMs and 20 NFs using immunohistochemistry. Appropriate positive and negative controls were included with study sections. p53 staining intensity was qualitatively graded by a dermatopathologist where: 0, no tumor cells staining; 1+, weak tumor cell staining; 2+, moderate tumor cells staining; 3+, strong tumor cells staining. The percentage of tumor cells staining positive in each staining intensity category (0, 1+, 2+, and 3+) was qualitatively determined by dermatopathologist review. Using the staining intensities observed for each DM, the Histo-score was then calculated using the following formula: [1×(% cells staining 1+)+2×(% cells staining 2+) +3×(% cells staining 3+)], resulting in a final score ranging from 0 to 300. 13,14 A 2-tailed t test was performed to determined statistical significance in p53 staining between the 2 groups (DMs and NFs).
MATERIALS AND METHODS

RESULTS
Twenty DMs were analyzed. Patient age ranged from 36 to 95 years (mean, 70.5 y; median, 70 y). They Table 2) . A total of 19/20 (95%) DMs were positive for p53. DM Histo-scores ranged from 0 to 300 (mean, 203; median, 260). Nuclear accumulation of p53 was seen in all p53 positive DMs (19/19); one (1/19) of which showed both nuclear and cytoplasmic staining. A total of 0/20 NFs were positive for p53 (2-tailed t test P-value <0.0001) (Figs. 1, 2 ). Clinical and immunohistochemical features are summarized in Table 3 .
DISCUSSION
Distinguishing NFs from DMs can be challenging in some cases. Differentiating DMs from NFs proves particularly challenging in the following scenarios: (1) an early DM that may not show significant cytologic atypia to be readily differentiated from NF; (2) when a superficial or limited biopsy of a DM is taken; (3) when a NF-like proliferation arises within severely sun-damaged skin, a location where DMs typically develop; and (4) when an intraepidermal group of melanocytes is located above a dermal population of spindled S100-positive cells. In these particular scenarios, a marker of differentiation would be desirable. To date, a reliable histologic marker to differentiate the 2 entities has remained elusive. S100 subtyping and CD34 fingerprinting have been proposed as potential avenues, but controversy remains about the practicality and reliability of these methods.
Based upon our immunohistochemical analysiswhich showed p53 to be positive in 95% of DMs and negative in 100% of NFs-we conclude that p53 can help to distinguish DMs from NFs. In addition, we observed nuclear accumulation of p53 in all p53 positive DMs, except in 1 case that showed both nuclear and cytoplasmic accumulation. This finding differs from previous reports of melanoma showing predominately cytoplasmic overexpression of p53. 15 We hypothesize that this stressinduced nuclear accumulation of p53 may be due to mutations resulting in decreased nuclear export and or enhanced nuclear import of p53 in this melanoma subtype. 16 Of interest, our study showed 95% positivity of 
